First Time Loading...
M

Medy Tox Inc
KOSDAQ:086900

Watchlist Manager
Medy Tox Inc
KOSDAQ:086900
Watchlist
Price: 141 900 KRW 8.65% Market Closed
Updated: Jun 3, 2024
Section:
 

Relative Value

The Relative Value of one Medy Tox Inc stock under the Base Case scenario is 301 338.39 KRW. Compared to the current market price of 141 900 KRW, Medy Tox Inc is Undervalued by 53%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
301 338.39 KRW
Undervaluation 53%
Relative Value
Price
M
Worst Case
Base Case
Best Case

Valuation Multiples

4.3
P/S
P/S
Price to Sales
4.3
vs History
73
vs Industry
69
Median 3Y
4.7
Median 5Y
6.7
Industry
7.8
Forward
3.8
More Details
108.8
P/E
P/E
Price to Earnings
108.8
vs History
15
vs Industry
2
Median 3Y
29.1
Median 5Y
32
Industry
24.7
Forward
22.9
More Details
70.7
P/OCF
P/OCF
Price to OCF
70.7
vs History
17
vs Industry
3
Median 3Y
33.2
Median 5Y
34.6
Industry
23.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-54.3
Median 5Y
-29.1
Industry
22.6
More Details
2
P/B
P/B
Price to Book Value
2
vs History
77
vs Industry
47
Median 3Y
2.2
Median 5Y
3.1
Industry
2.5
More Details
4.5
EV/S
EV/S
Enterprise Value to Sales
4.5
vs History
74
vs Industry
58
Median 3Y
4.9
Median 5Y
7
Industry
7.1
Forward
3.9
More Details
7.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.4
vs History
76
vs Industry
48
Median 3Y
8.2
Median 5Y
11.5
Industry
8.7
More Details
30.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
30.4
vs History
41
vs Industry
4
Median 3Y
17.2
Median 5Y
25.4
Industry
4.6
Forward
15.3
More Details
56.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
56.8
vs History
19
vs Industry
2
Median 3Y
26.2
Median 5Y
26.2
Industry
4.5
Forward
21
More Details
72.9
EV/OCF
EV/OCF
Enterprise Value to OCF
72.9
vs History
17
vs Industry
2
Median 3Y
35.4
Median 5Y
36.8
Industry
6.3
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
100
Median 3Y
-39.1
Median 5Y
-30
Industry
3.9
More Details
1.7
EV/IC
EV/IC
Enterprise Value to IC
1.7
vs History
80
vs Industry
52
Median 3Y
1.8
Median 5Y
2.4
Industry
4.6
More Details

Multiples Across Competitors

Competitors Multiples
Medy Tox Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Medy Tox Inc
KOSDAQ:086900
955B KRW 4.3 108.8 30.4 56.8
US
Abbvie Inc
NYSE:ABBV
284B USD 5.2 47.6 13.4 20.6
US
Amgen Inc
NASDAQ:AMGN
166.3B USD 5.6 44.1 18.6 30.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD 11.8 30 25.2 26.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
110B USD 8.4 28.5 23.1 25.6
AU
CSL Ltd
ASX:CSL
135.9B AUD 6.4 36.6 22.1 27.4
US
Gilead Sciences Inc
NASDAQ:GILD
80B USD 2.9 165 8.4 11.1
US
Moderna Inc
NASDAQ:MRNA
56.6B USD 10.9 -9.5 -10.7 -9.5
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
33.8B USD 3.5 28.9 14.7 18.4
IE
Horizon Therapeutics PLC
NASDAQ:HZNP
26.6B USD 7.3 60.8 27.9 47

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 143,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.